98%
921
2 minutes
20
Background: Glomerular hyperfiltration is well recognized as an early renal alteration in subjects with diabetes mellitus. However, what is not well-known is whether hyperfiltration also occurs in the early stages of hyperglycaemia, for instance in prediabetes. Identifying subjects with glomerular hyperfiltration from among those with prediabetes might be helpful to implement preventive and therapeutic strategies. This study aimed to investigate the association of prediabetes with glomerular hyperfiltration and its associated variables.
Methods: A representative sample of 9238 people aged ≥ 30 years and whose entire clinical and laboratory data were available, were included in this study. Hyperfiltration was defined as an estimated glomerular filtration rate (eGFR) above the age- and gender-specific 95th percentile. The eGFR was assessed using the Chronic Kidney Disease Epidemiology Collaboration equation.
Results: After adjustment for age, gender, body mass index, systolic blood pressure and diastolic blood pressure, cholesterol, log (triglycerides), high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, serum uric acid, smoking status, hypertension, and use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, fasting plasma glucose (FPG) was found to be independently positively associated with eGFR. The hazard ratios (95% confidence interval) for hyperfiltration were 1.61 (1.28-2.03) and 2.30 (1.89-2.79) for prediabetes and diabetes, respectively, when compared with participants with normoglycemia.
Conclusion: Prediabetes was associated with glomerular hyperfiltration. Longitudinal studies are needed to investigate whether hyperfiltration in prediabetes is associated with a later decline in eGFR.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s40620-018-0524-0 | DOI Listing |
J Clin Endocrinol Metab
September 2025
AURA (Association pour l'Utilisation du Rein Artificiel dans la région parisienne), F-75014 Paris, France.
Purpose: Obesity is an independent risk factor for chronic kidney disease, and accurate estimation of the glomerular filtration rate (GFR) is crucial. However, limited data are available on the performance of the European Kidney Function Consortium (EKFC) equation in individuals with overweight or obesity. We evaluated the performance of the EKFC equation by comparing its estimated GFR (eGFR) to values obtained from the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and machine learning (ML) models, using measured GFR (mGFR, obtained via plasma iohexol clearance) as a reference standard in a cohort of patients with overweight or obesity.
View Article and Find Full Text PDFClin Transplant
September 2025
Department of Nephrology, Atılım University Faculty of Medicine, Ankara, Turkey.
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have demonstrated renoprotective and cardioprotective benefits beyond their antiglycemic effects. Their potential utility in kidney transplant recipients (KTRs) for preserving graft function and reducing rejection risk is currently under active investigation. Preliminary studies indicate that SGLT-2i therapy stabilizes estimated glomerular filtration rate (eGFR), decreases glomerular hyperfiltration, and improves metabolic outcomes in KTRs.
View Article and Find Full Text PDFSurg Obes Relat Dis
August 2025
Department of Internal Medicine, Division of Nephrology and Hypertension, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan.
Background: Patients with severe obesity have glomerular hyperfiltration even without the overt renal dysfunction, but improvements are reported with metabolic surgery (MS). However, the mechanism underlying these effects of MS has not been investigated.
Objective: The aim of the present study was to determine whether MS for patients with severe obesity alters retroperitoneal adipose tissue (RAT) and kidney volume (KV), and whether these alterations lead to improvements in renal function and hypertension (HTN).
Metabolites
August 2025
Grupo de Investigación en Enfermedades Cardiorrenales y Metabólicas, Departamento de Medicina y Cirugía, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, CEU Universities, C/Santiago Ramón y Cajal s/n, 46115 Valencia, Spain.
: Sodium-glucose cotransporter-2 inhibitors (SGLT2is), initially developed as antihyperglycemic agents, have emerged as multifunctional therapeutics with profound cardiorenal and metabolic benefits. Their unique insulin-independent mechanism, targeting renal glucose reabsorption, distinguishes them from conventional antidiabetic drugs. : SGLT2is induce glycosuria, reduce hyperglycemia, and promote weight loss through increased caloric excretion.
View Article and Find Full Text PDFFront Med (Lausanne)
August 2025
Department of Nephrology, Tianyou Hospital, Wuhan University of Science and Technology, Wuhan, China.
Diabetic kidney disease (DKD) has emerged as the leading cause of chronic kidney disease (CKD) worldwide, surpassing primary glomerular disorders in prevalence. Despite recent therapeutic advances, current treatment strategies primarily alleviate symptoms rather than address the underlying pathogenic mechanisms, highlighting an urgent need for targeted, mechanism-based interventions. The pathogenesis of DKD involves a complex interplay of metabolic, hemodynamic, inflammatory, oxidative, and fibrotic pathways.
View Article and Find Full Text PDF